CureVac (NASDAQ:CVAC) Trading 4.7% Higher – What’s Next?

CureVac (NASDAQ:CVAC) shares were up 4.7% during mid-day trading on Thursday . The company traded as high as $4.32 and last traded at $4.26. Approximately 356,735 shares traded hands during trading, a decline of 79% from the average daily volume of 1,710,864 shares. The stock had previously closed at $4.07.

CureVac Stock Performance

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $3.21 and a 200 day moving average price of $3.17. The stock has a market cap of $917.91 million, a PE ratio of 7.45 and a beta of 2.50.

Institutional Investors Weigh In On CureVac

Several large investors have recently modified their holdings of CVAC. Signaturefd LLC boosted its position in CureVac by 26.9% during the 3rd quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock valued at $82,000 after acquiring an additional 5,927 shares in the last quarter. Green Alpha Advisors LLC boosted its position in CureVac by 41.3% during the third quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock valued at $80,000 after purchasing an additional 7,979 shares in the last quarter. Ballentine Partners LLC grew its stake in CureVac by 58.6% in the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after purchasing an additional 8,406 shares during the last quarter. Private Advisor Group LLC bought a new position in CureVac in the third quarter worth about $30,000. Finally, International Assets Investment Management LLC purchased a new stake in shares of CureVac during the third quarter valued at about $35,000. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.